AEterna Zentaris

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women's health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.
Type
Public
HQ
Montreal, CA
Employees
46 (est)-47%
AEterna Zentaris is headquartered in Montreal, CA

AEterna Zentaris Locations

Montreal, CA
Summerville, US
Frankfurt am Main, DE

AEterna Zentaris Metrics

AEterna Zentaris Summary

Market capitalization

$40.7 M

Closing share price

$3.45
AEterna Zentaris's latest market capitalization is $40.7 M.

AEterna Zentaris Market Value History

20% of current employees of AEterna Zentaris are female and 80% are male.

AEterna Zentaris Company Life

You may also be interested in